Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Veru Inc.
Mon., May 24, 2021, 7:30 a.m.·9 min read
VERU
+1.11%
-- Presentation of Phase 2 trial clinical trial data from patients with AR+ER+HER2- metastatic breast cancer demonstrating that the antitumor efficacy of enobosarm, a selective androgen receptor targeting agent, treatment is dependent on the magnitude of expression of androgen receptor (AR) in breast cancer tissue --
-- Presentation of Phase 1b/2 updated clinical trial results of sabizabulin (VERU-111), an oral androgen receptor transport disruptor, in metastatic castration and androgen receptor targeting agent resistant prostate cancer --
MIAMI, May 24, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that two abstracts were accepted for presentation at the 2021 American Society of Clinical Oncology Annual Meeting which will be held virtually from June 4-8, 2021.
Poster Discussion Session – Breast Cancer (Metastatic)
Abstract #1020: Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international Phase 2 clinical study
Presenter: Carlo Palmieri, BSc, MB BS, PhD, FRCP, Professor of Translational Oncology & Medical Oncologist, University of Liverpool
Poster Presentation - Genitourinary Cancer—Prostate, Testicular, and Penile
Abstract #5056: Sabizabulin (VERU-111), an oral cytoskeleton disruptor, to treat men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent
Presenter: Dr. Mark C. Markowski, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Additional information on the meeting can be found on the ASCO website globenewswire.com
“These exciting clinical results have allowed us to advance two novel agents, enobosarm and sabizabulin into Phase 3 registration trials. The Phase 3 ARTEST clinical trial of enobosarm monotherapy in the 3rd line metastatic setting in subjects with AR+ER+ metastatic breast cancer is expected to begin enrolling in June 2021 and the Phase 3 VERACITY trial for sabizabulin in men with metastatic castration resistant prostate cancer who have failed at least one androgen receptor targeting agent is expected to initiate in early June 2021,” said Dr. Mitchell Steiner, Chairman, President and CEO of Veru Inc. “We are a step closer to potentially bringing these important drugs to large and growing unmet medical need indications in treatment of refractory breast and prostate cancers.” |
